JPMorgan on Sage Therapeutics (SAGE): 'we are encouraged there were no safety concerns'
Tweet Send to a Friend
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $29.00 price target on Sage Therapeutics (NASDAQ: SAGE)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
